THOMAS NOWOTNY: Open Payments
NPI 1134284904 · ST LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,733 in 178 payments from 21 companies in 2025. Trend: 2023 $1,890 · 2024 $2,802 · 2025 $2,733
Food & beverage: $2,722Education: $11
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 25 | $433 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $345 |
| ABBVIE INC. | 27 | $279 |
| Alkermes, Inc. | 14 | $243 |
| Otsuka America Pharmaceutical, Inc. | 17 | $242 |
| Supernus Pharmaceuticals, Inc. | 19 | $195 |
| Vanda Pharmaceuticals Inc. | 10 | $184 |
| Lundbeck LLC | 8 | $143 |
| Axsome Therapeutics, Inc. | 8 | $143 |
| Janssen Pharmaceuticals, Inc | 4 | $93 |
Products named: COBENFY, CAPLYTA, REXULTI, VRAYLAR, ARISTADA, Qelbree, FANAPT, Auvelity.
Industry payments across MO — which companies pay providers there.
